Conference Coverage From EASL

[Guest guest]

INDEPENDENT CONFERENCE COVERAGE 2011 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

CLICK TO ACCESSConference Coverage From Berlin, Germany

CCO's Independent Conference Coverage of EASL 2011 in Berlin, Germany, includes Capsule Summaries of the most clinically relevant data presented at the meeting, an original CCO highlights slideset, and a CME-certified Expert Analysis.

To browse available coverage, click here or select a link below.

Capsule Summaries:Capsule Summaries are “quick read†reviews of key oral and poster presentations, handpicked by leading experts in hepatology. The comprehensive contents are based on the actual data presented at the meeting—providing the most up-to-date information.

CLICK TO ACCESSFrom Podium to Practice: Clinical Impact of New Data From EASL 2011Click a link below to access Capsule Summaries

Addition of Alisporivir to PegIFN/RBV Yields Superior Efficacy vs PegIFN/RBV Alone in Treatment-Naive Patients With Genotype 1 HCV – Link

Previous Treatment Response Categorization Better Predictor of SVR Following Telaprevir-Based Therapy Than Response to 4-Week PegIFN/RBV Lead-in Phase – Link

Boceprevir Plus PegIFN/RBV Safe and Effective in Genotype 1 HCV–Infected Patients With Advanced Fibrosis/Cirrhosis – Link

Telaprevir-Resistant HCV Variants Present at Time of Treatment Failure Replaced by Wild-Type Virus Over Time in Majority of Patients – Link

Among 1 Genotype HCV–Infected Patients Not Achieving SVR With Boceprevir-Based Regimen, Resistance-Associated Variants More Common in Those With Poor Response to 4-Week PegIFN/RBV Lead-in – Link

PSI-938 and PSI-7977 Purine and Pyrimidine Nucleotide Analogues Demonstrate Favorable Safety/Tolerability and Robust 14-Day Antiviral Activity Alone and in Combination Against Genotype 1 HCV – Link

ASPIRE Interim Data: TMC435 Plus PegIFN/RBV Demonstrates High Rates of Response Through Week 24 in Patients With Genotype 1 HCV Who Failed Previous PegIFN/RBV – Link

This Conference Coverage is located online at:http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Berlin%202011.aspx

Coming Soon: CME-Certified Expert Analysis

2011 Annual Meeting of the European Association for the Study of the LiverLeading experts discuss the most clinically relevant data from the meeting in Berlin, Germany, in a CME-certified Expert Analysis.

This program is located online at:http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Berlin%202011.aspx

Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.

Supported by educational grants from Bristol-Myers Squibb; Pharmasset, Inc.; and Vertex.

Clinical Care Options Hepatitis

GET MORE FROM CCO2011 Annual CCO HIV and Hepatitis C Symposium

Register today for the 2011 Annual CCO HIV and Hepatitis C Symposium for a review of the most important scientific and clinical advances over the past year, including expert guidance on integrating novel HCV agents into clinical care. Click here for more information.

Conference CoverageJournal OptionsManagement SeriesTreatment UpdatesInteractive Cases

Live MeetingsRSS / PodcastsMy CME TrackerFree BookstoreSlide

Downloads

2011 Clinical Care Options, LLC. 1894 Preston White Drive, Suite 110, Reston, VA 20191-5433

To ensure you receive Clinical Care Options educational materials by email,please add info@... to your contacts or address book.

Not a member yet? Click here